U.S. President Donald Trump has taken a significant step in federal drug policy by signing an executive order on Thursday to potentially reclassify marijuana as a less dangerous drug, allowing for expanded medical research opportunities. This move would shift marijuana from its current Schedule I classification, which includes drugs like heroin and LSD, to a Schedule III substance, placing it alongside substances such as ketamine and certain anabolic steroids.
While reclassification by the Drug Enforcement Administration would not legalize recreational marijuana nationwide, it could lead to changes in regulation and alleviate the heavy tax burden on the cannabis industry. President Trump cited widespread support for the decision, particularly from individuals experiencing severe pain and in need of alternative treatment options. Notably, the Justice Department under Trump’s predecessor, Joe Biden, also proposed reclassifying marijuana to a Schedule III substance.
Despite some opposition within his own party, President Trump’s executive order is expected to expedite the review process by the DEA. Currently, many states have legalized marijuana for either recreational or medical use, but federal laws remain stringent, potentially exposing individuals to federal prosecution.
Recent polling data from Gallup indicates a growing trend of support for marijuana legalization among Americans, with approval ratings rising from 36% in 2005 to 68% in the past year. The executive order also aims to enhance research and access to CBD, a hemp-derived product gaining popularity, with a new Medicare program set to provide older adults with access to legal CBD recommended by healthcare providers at no cost.
However, not all Republicans are in favor of reclassification. A group of over 20 Republican senators, including staunch allies of Trump, penned a letter urging the president to maintain marijuana’s Schedule I status, citing concerns over public health and safety. Trump, who has not committed to decriminalizing marijuana, has focused his efforts on combating other drugs like fentanyl, declaring it a weapon of mass destruction through another executive order.
In conclusion, President Trump’s executive order on marijuana reclassification marks a pivotal shift in federal drug policy, reflecting evolving attitudes towards cannabis use and paving the way for increased research and potential regulatory changes in the future.